Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

181. The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease

for palliative care. The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 42Dialysis is the process of filtering the blood to remove any harmful waste products, extra salt and water. There are two forms of dialysis: haemodialysis and peritoneal dialysis (NHS Choices, 2013a). Haemodialysis is the removal (...) NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 42healthcare professionals to check the regulatory status of any intended use of the technology in other indications and settings. About the technology CE marking CE marking The NxStage System One first received a CE mark in April 2004. The current CE mark is held

2014 National Institute for Health and Clinical Excellence - Advice

182. Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines

Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Outpatient self-dialysis programs for patients with chronic renal conditions: clinical and cost-effectiveness, safety, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One health technology assessment and one non-randomized study were identified regarding outpatient self-dialysis programs

2014 Health Technology Assessment (HTA) Database.

183. KHA-CARI commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease

KHA-CARI commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease Original Article Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease MATTHEW A ROBERTS Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia Correspondence: Dr Matthew Roberts, Dept of Nephrology, Box Hill Hospital, Eastern Health, Level 2, 5 Arnold St (...) on cardiovascular and renal outcomes: A systematic review and meta-analysis. Plos Med. 2012; 9: e1001293. 2. Eckardt KU, Kasiske BL. Kidney disease: Improving global outcomes. Nat. Rev. Nephrol. 2009; 5: 650–57. 3. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. (Suppl.) 2012; 2: 337–414. 4. Levin NW, Kotanko P, Eckardt KU et al. Blood pressure in chronic kidney disease

2014 KHA-CARI Guidelines

184. KHA-CARI commentary on the KDIGO Clinical Practice Guideline for lipid management in chronic kidney disease

KHA-CARI commentary on the KDIGO Clinical Practice Guideline for lipid management in chronic kidney disease Commentary KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease SUETONIA C PALMER, 1,2 GIOVANNI FM STRIPPOLI 2,3,4,5,6 and JONATHAN C CRAIG 2,3 1 Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand; 2 Cochrane Renal Group, 3 Sydney School of Public Health, University of Sydney, Sydney, New South Wales (...) cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181–92. 4. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009; 360: 1395–407. 5. Eckardt K, Kasiske B. Kidney disease: Improving global outcomes. Nat. Rev. Nephrol. 2009; 5: 650–57. 6. Kidney Disease: Improving Global Outcomes (KDIGO

2014 KHA-CARI Guidelines

185. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. (Abstract)

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Calcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels in people who have chronic kidney disease (CKD), but the benefits and harms on patient-level outcomes are uncertain. Since this review was first published in 2006 showing that evidence for calcimimetics was largely restricted to biochemical outcomes, additional studies have been conducted. This is an update of a review first published (...) in 2006.To evaluate the benefits and harms of cinacalcet on patient-level outcomes in adults with CKD.MEDLINE, EMBASE, CENTRAL and conference proceedings were searched for randomised controlled trials (RCTs) evaluating any calcimimetic against placebo or another agent in adults with CKD (persistent albuminuria > 30 mg/g with or without reduced glomerular filtration rate (GFR) (below 60 mL/min/1.73 m²)). We updated searches to 7 February 2013 including the Cochrane Renal Group's Specialised Register

2014 Cochrane

186. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected with HIV

Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected with HIV Practice Guidelines Search Search Practice Guidelines Practice guidelines are systematically developed statements to assist practitioners and patients in making decisions about appropriate health care for specific clinical circumstances. Attributes of good guidelines include validity, reliability, reproducibility, clinical applicability, clinical flexibility, clarity, multidisciplinary process (...) , review of evidence, and documentation. [Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, 1990] Infectious Diseases Society of America Fax: © Copyright IDSA 2019 This website uses cookies We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable

2014 Infectious Diseases Society of America

187. Management of Chronic Kidney Disease (CKD) in Primary Care

and effective assessment of the patient's condition • Optimize the use of therapy to reduce disease progression, reduce symptoms of CKD, and enhance patient functionality • Minimize preventable complications and morbidity • Emphasize the use of personalized, proactive, patient-driven care December 2014 Page 5 of 117 Background Chronic kidney disease is one of the most common serious medical conditions affecting adults in the United States (US). The Centers for Disease Control and Prevention (CDC) estimate (...) to display each step in the algorithm, and arrows connect the numbered boxes indicating the order in which the steps should be followed. [10] Rounded rectangles represent a clinical state or condition. Hexagons represent a decision point in the guideline, formulated as a question that can be answered Yes or No. Rectangles represent an action in the process of care. December 2014 Page 12 of 117 December 2014 Page 13 of 117 Recommendations # Recommendation Strength Evaluation for Chronic Kidney Disease

2014 VA/DoD Clinical Practice Guidelines

188. Cohort study: Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease

is associated with increased risk of chronic and end-stage kidney disease Reem A Asad , Vesna D Garovic Statistics from Altmetric.com Commentary on Wang IK , Muo CH , Chang YC , et al . Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study . Implications for practice and research Women with a history of hypertensive pregnancy disorders may have an elevated risk of future chronic kidney disease (CKD) and end-stage renal disease (ESRD). Follow-up (...) Cohort study: Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password

2014 Evidence-Based Nursing

189. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom Full Text available with Trip Pro

A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom (...) of hyperphosphataemia, associated with chronic kidney disease, in patients who had been receiving dialysis for an average of 38.2 months. Interventions The intervention was sevelamer carbonate (6.9g/day) for the initial treatment of hyperphosphataemia. The comparator was calcium-based phosphate binders, which were those most commonly used in the UK; it was assumed that 70% of patients received calcium acetate (5.3g/day) and 30% received calcium carbonate (4.9g/day). Location/setting UK/secondary care. Methods

2013 NHS Economic Evaluation Database.

190. [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents]

[Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents] Terapias biológicas en el tratamiento de la anemia asociada a insuficiencia renal crónica: eficacia y seguridad comparada entre los agentes estimuladores de la eritropoyesis [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different (...) erythropoiesis-stimulating agents] Terapias biológicas en el tratamiento de la anemia asociada a insuficiencia renal crónica: eficacia y seguridad comparada entre los agentes estimuladores de la eritropoyesis [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents] Abdel–Kader Martín, L; Castillo Muñoz, MA; Ubago Pérez, R; Vega Coca, MD; Rodríguez López, R Record Status This is a bibliographic

2013 Health Technology Assessment (HTA) Database.

191. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis

Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

192. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Full Text available with Trip Pro

Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed clinical practice guidelines in 2012 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving renal replacement therapy.The KDIGO CKD Guideline Development Work Group defined the scope

2013 Annals of Internal Medicine

193. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Full Text available with Trip Pro

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Since the first description of the association between chronic kidney disease and heart disease, many epidemiological studies have confirmed and extended this finding. As chronic kidney disease progresses, kidney-specific risk factors for cardiovascular events and disease come into play. As a result, the risk for cardiovascular disease is notably increased in individuals with chronic kidney disease. When (...) adjusted for traditional cardiovascular risk factors, impaired kidney function and raised concentrations of albumin in urine increase the risk of cardiovascular disease by two to four times. Yet, cardiovascular disease is frequently underdiagnosed and undertreated in patients with chronic kidney disease. This group of patients should, therefore, be acknowledged as having high cardiovascular risk that needs particular medical attention at an individual level. This view should be incorporated

2013 Lancet

194. Chronic kidney disease: global dimension and perspectives. (Abstract)

Chronic kidney disease: global dimension and perspectives. Chronic kidney disease is defined as a reduced glomerular filtration rate, increased urinary albumin excretion, or both, and is an increasing public health issue. Prevalence is estimated to be 8-16% worldwide. Complications include increased all-cause and cardiovascular mortality, kidney-disease progression, acute kidney injury, cognitive decline, anaemia, mineral and bone disorders, and fractures. Worldwide, diabetes mellitus (...) is the most common cause of chronic kidney disease, but in some regions other causes, such as herbal and environmental toxins, are more common. The poorest populations are at the highest risk. Screening and intervention can prevent chronic kidney disease, and where management strategies have been implemented the incidence of end-stage kidney disease has been reduced. Awareness of the disorder, however, remains low in many communities and among many physicians. Strategies to reduce burden and costs related

2013 Lancet

195. A Simple Tool to Predict End-Stage Renal Disease within 1 Year in Elderly Adults with Advanced Chronic Kidney Disease Full Text available with Trip Pro

A Simple Tool to Predict End-Stage Renal Disease within 1 Year in Elderly Adults with Advanced Chronic Kidney Disease To develop and validate a model to predict 1-year risk of end-stage renal disease (ESRD) in elderly subjects with advanced chronic kidney disease (CKD).Retrospective.Veterans Affairs Medical Center.Individuals aged 65 and older with CKD with an estimated glomerular filtration rate (eGFR) less than 30 mL/min per 1.73 m(2) .The outcome was ESRD within 1 year of the index eGFR. Cox (...) ). The C-index for the recently published Tangri model in the validation cohort was 0.780.A new model using commonly available clinical measures shows excellent ability to predict the onset of ESRD within the next year in elderly adults. The Tangri model also had good predictive ability. Individuals and physicians can use these risk models to inform decisions regarding preparation for renal replacement therapy in individuals with advanced CKD.© 2013, Copyright the Authors Journal compilation © 2013

2013 EvidenceUpdates

196. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone Full Text available with Trip Pro

An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone The OSCAR study was a multicenter, prospective randomized open-label blinded end-point study of 1164 Japanese elderly hypertensive patients comparing the efficacy of angiotensin II receptor blocker (ARB) uptitration to an ARB plus calcium channel blocker (CCB (...) ) combination. In this prospective study, we performed prespecified subgroup analysis according to baseline estimated glomerular filtration rate (eGFR) with chronic kidney disease (CKD) defined as an eGFR <60 ml/min per 1.73 m(2). Blood pressure was lower in the combined therapy than in the high-dose ARB cohort in both groups with and without CKD. In patients with CKD, significantly more primary events (a composite of cardiovascular events and noncardiovascular death) occurred in the high-dose ARB group

2013 EvidenceUpdates Controlled trial quality: uncertain

197. Chronic kidney disease (stage 4 or 5): management of hyperphosphatemia

and soft tissue calcification. For adults with stage 4 or 5 CKD who are not on dialysis, the UK Renal Association guidelines recommend that serum phosphate be maintained at between 0.9 and 1.5 mmol/l. For adults with Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia (CG157) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 21stage 5 CKD who are on dialysis, it is recommended that serum (...) Chronic kidney disease (stage 4 or 5): management of hyperphosphatemia Chronic kidne Chronic kidney disease (stage 4 or 5): y disease (stage 4 or 5): management of h management of hyperphosphataemia yperphosphataemia Clinical guideline Published: 13 March 2013 nice.org.uk/guidance/cg157 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline

2013 National Institute for Health and Clinical Excellence - Clinical Guidelines

198. Risk factors for early chronic kidney disease

insufficiency. Internal Medicine Journal. 2004; 34: 50-7. 10. Dunstan DW, Zimmet PZ, Welborn TA et al, Diabetes and related disorders in Australia 2000., in International Diabetes Institute. 2001: Melbourne. 11. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Annals of Internal Medicine. 2004; 140: 167-74. 12. McCullough PA. Cardiovascular risk reduction and preservation of renal function in the early nephropathy patient. Advances in Chronic Kidney Disease (...) recommendations. BACKGROUND Chronic kidney disease (CKD) is a major public health problem in Australia and throughout the world. Based on data from the AusDiab study [1], it is estimated that over 1.7 million Australian adults have at least moderately severe kidney failure, defined as an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m 2 . This pernicious condition is often not associated with significant symptoms or urinary abnormalities and is unrecognized in 80-90% of cases [1-3]. CKD

2013 KHA-CARI Guidelines

199. Vitamin D therapy (supplementation) in early chronic kidney disease

regularly audit 25-hydroxyvitamin D levels and vitamin D supplementation in their practices. The association of these practices with clinical outcomes, such as chronic kidney disease mineral and bone disorder (CKD-MBD), cardiovascular events and renal function decline, should be evaluated. BACKGROUND The current guideline is focused on vitamin D therapy in CKD stages 1-3. Vitamin D deficiency is not uncommon in the general and CKD populations[1, 2] Common factors causing low serum vitamin D levels (...) Vitamin D therapy (supplementation) in early chronic kidney disease ____________________________________________________________________________________________________________ Early Chronic Kidney Disease July 2012 Page 1 of 12 Vitamin D therapy (supplementation) in early chronic kidney disease Date written: July 2012 Author: Maria Chan, David Johnson GUIDELINES a. We suggest vitamin D deficiency (25-hydroxyvitamin D 70 years – 15 µg (600 IU) (where 1µg = 40 IU) Note: Few foods contain

2013 KHA-CARI Guidelines

200. Symptoms, natural history and outcomes of early chronic kidney disease

et al. Chronic Kidney Disease and Drinking Status in Relation to Risks of Stroke and Its Subtypes. Stroke. 2011; 42: 2531-37. 14. Cheng T-YD, Wen S-F, Astor BC et al. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. Am J Kidney Dis. 2008; 52: 1051-60. 15. Chien K-L, Hsu H-C, Lee Y-T et al. Renal function and metabolic syndrome components on cardiovascular and all-cause mortality. Atherosclerosis. 2008; 197: 860-67. 16. Deo R (...) and results Cohen et al (2007) [38] 153 Cohort 92 Participants with CKD were recruited from the George Washington University Medical Centre Outpatient Clinic. 61Controls consisted of general medicine outpatients without CKD. NA 69% of patients with chronic kidney disease experienced pain; 55% had disordered sleep. Depression, burden of illness and life satisfaction were associated with pain. Depression, burden of disease, social support and frequency of pain were associated with disordered sleep

2013 KHA-CARI Guidelines